Prospective Athlete's Heart Study
ConditionAthlete Heart
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age14-23
SponsorUniversitaire Ziekenhuizen KU Leuven
About this trial
The Pro@Heart (Prospective Athlete's Heart) study is an international multicentre long-term prospective trial. The primary objective of the Pro@Heart study is to investigate the impact of training load (i.e. accurately evaluated in term of type, frequency, duration and intensity) and genotype on the variability of structural, functional and electrical exercise induced cardiac remodeling (EICR) in young competitive endurance athletes. The second objective is to determine how EICR, training load and genotype are associated with physical performance, health benefits and cardiac pathology (e.g. exercise-related cardiomyopathies and arrhythmias) during follow-up over several decades.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Males and females aged 14-23 years old
Triathlon
Cycling
Distance running (≥ 1500 meters)
Disqualifiers
Medical history of cardiovascular disease
Current smoker of past history of smoking
Diabetes mellitus
Trial population
Athletes aged 14 to 23 years recruited from elite endurance sports programs and organisations including Cycling Vlaanderen, Triatlon Vlaanderen, Belgian Cycling, Cycling Australia, Rowing Australia and Athletics Australia and from sports performance centres including Nottebohm Antwerpen, Bakala Academy Leuven and Adlon Hasselt. Volunteers recruited by means of 'word of mouth' and social media campaigns within elite endurance sporting circles. Non-athletes consist of age and gender matched university and college students recruited from Australian and Belgian universities in addition to social media campaigns.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No intervention
Other interventionNo intervention
Treatment groups
450 Participants
are divided into 2 treatment groupsGroup A: Athletes1 intervention
Group B: Non-athletes1 intervention
Trial outcomes
Primary outcomes
1
Genotype
Rare and common variants in cardiomyopathy associated genes
Time frame
Baseline2
Training load
Duration and intensity of training
Time frame
Baseline to 20 years3
Atrial fibrillation
Time frame
Baseline to 20 years4
Ventricular arrhythmias
Ventricular ectopic beats, non-sustained and sustained ventricular tachycardia
Time frame
Baseline to 20 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Universitaire Ziekenhuizen KU Leuven
Lead sponsor
Baker Heart and Diabetes Institute
Collaborator
Victor Chang Cardiac Research Institute
Collaborator
University Hospital, Antwerp
Collaborator
Jessa Hospital
Collaborator
Source ClinicalTrials.gov